EMI (Encore Medical) ROIC %: -100.30% (As of Dec. 2025)


What is Encore Medical ROIC %?

Encore Medical EMI ROIC % is -100.30% as of Dec. 2025.

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Encore Medical's annualized return on invested capital (ROIC %) for the quarter that ended in Dec. 2025 was -100.30%.

As of today (2026-06-25), Encore Medical's WACC % is 0.00%. Encore Medical's ROIC % is 0.00% (calculated using TTM income statement data). Encore Medical earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Encore Medical  (AMEX:EMI) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Encore Medical's WACC % is 0.00%. Encore Medical's ROIC % is 0.00% (calculated using TTM income statement data). Encore Medical earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Encore Medical ROIC % Related Terms


Encore Medical ROIC % Historical Data

* Premium members only.

The historical data trend for Encore Medical's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Encore Medical ROIC % Chart

Encore Medical Annual Data
Trend Dec23 Dec24 Dec25
ROIC %
-128.95 -217.35 -64.26

Encore Medical Quarterly Data
Dec23 Sep24 Dec24 Jun25 Sep25 Dec25
ROIC % Get a 7-Day Free Trial -241.73 -467.02 0.00 -181.34 -100.30

EMI vs : ROIC % Comparison

For the Medical Instruments & Supplies subindustry, Encore Medical's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Encore Medical ROIC % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Encore Medical's ROIC % distribution charts can be found below:

* The bar in red indicates where Encore Medical's ROIC % falls into.



Encore Medical ROIC % Calculation

Encore Medical's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2025 is calculated as:

ROIC % (A: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2024 ) + Invested Capital (A: Dec. 2025 ))/ count )
=-0.829 * ( 1 - 0% )/( (0.561 + 2.019)/ 2 )
=-0.829/1.29
=-64.26 %

where

Encore Medical's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Dec. 2025 is calculated as:

ROIC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-1.34 * ( 1 - 0% )/( (0.653 + 2.019)/ 2 )
=-1.34/1.336
=-100.30 %

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROIC % →
What does a ROIC % of -100.30% mean?
Encore Medical (EMI) has a ROIC % of -100.30% as of Dec. 2025. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on Encore Medical and its competitors.
Is Encore Medical's ROIC % too high?
Encore Medical's current ROIC % is -100.30%.
How does Encore Medical's ROIC % compare to ?
Encore Medical's ROIC % of -100.30% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROIC % is 1.27. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROIC % for a Medical Devices & Instruments company?
The median ROIC % among Medical Devices & Instruments companies is 1.27, based on 847 companies in the industry. Companies in the top quartile (top 25%) have a ROIC % significantly above this median, while those in the bottom quartile fall well below. However, ROIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROIC % mean?
A high ROIC % can signal that a stock is expensive relative to its fundamentals. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on Encore Medical and its competitors. For the Medical Devices & Instruments industry, the median ROIC % is 1.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Encore Medical's current ROIC % is -100.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Encore Medical stock overvalued right now?
Encore Medical (EMI) has a current ROIC % of -100.30%. The current ROIC % is -100.30%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROIC % calculated?
ROIC % is calculated from a company's financial statements. For Encore Medical (EMI), the current ROIC % is -100.30% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Encore Medical Business Description

Comparable Companies
Address 2975 Lone Oak Drive, Suite 140, Eagan, MN, USA, 55121
Encore Medical Inc develops, manufactures, and markets septal occlusion devices for the repair of certain cardiac defects. Its products have been implanted in approximately 35,000 patients outside the United States. Its closure device is designed to correct a cardiac defect, generally diagnosed in adulthood, known as a patent foramen ovale (PFO). The company also currently market and sell septal occlusion devices for the transcatheter closure of atrial septal defects (ASD).